ROSSARI Rossari Biotech Q2 FY27 results (Jul–Sep 2026) and concall
Rossari Biotech Limited reported a strong Q2 FY27, achieving its highest-ever quarterly revenue of ₹698 crores and EBITDA of ₹87 crores, representing 19% and 21% YoY growth respectively. Gross margins expanded to 31.6% due to an improved product mix. The company made significant progress in debt reduction, with net debt falling to ₹221 crores, and improved working capital efficiency. However, challenges persisted from volatile raw material prices, high freight costs, and cautious customer demand, which impacted core B2B EBITDA margins.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q2 FY27: revenue up 17.9%, net profit up 9.7% against the same quarter last year.
| Line item | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | Q2 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 368 | 427 | 366 | 420 | 451 +23% | 516 +21% | 482 +32% | 495 +18% |
| EBITDA | 50 | 52 | 44 | 50 | 50 +0% | 64 +23% | 56 +27% | 57 +14% |
| Net profit | 31 | 32 | 26 | 31 | 31 +0% | 55 +72% | 34 +31% | 34 +10% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
